15% weight benzyl benzoate per volume of formulation wherein the ricinoleate
vehicle is castor oil and the formulation is adapted for attaining
a therapeutically significant blood plasma fulvestrant concentration of at least 8.5 ngml-1.
2. The use as claimed in claim 1, whereas the formulation is present in a syringe or vial.
5. Auxiliary to no. 4 above, the Patent is to be upheld with the following
limited claims:
1. Use of fulvestrant in the preparation of a pharmaceutical formulation for the treatment of breast cancer by intra-muscular ad-